Text Size: A A A      Contrast:       
 

Novartis RAVEN - Central Retinal Vein Occlusion (CRVO)

Brolucizumab Versus Aflibercept in Patients With CRVO  (RAVEN)

Condition or Disease

Intervention / Treatment

Phase

Sponsor

Status

Branch Retinal Vein Occlusion

Brolucizumab
Aflibercept

Phase 3

Novartis

Enrolling

 Detailed Description:

The purpose of this study is to evaluate the efficacy and safety of brolucizumab in treatment of patients with macular edema (ME) secondary to central retinal vein occlusion (CRVO).

Following a 4-week maximum screening period, patients will be randomized and treated for approximately 76 weeks. Treatment visits will be scheduled in 4-week intervals. After 6 initial monthly injections of brolucizumab or aflibercept (loading phase), subjects will enter a one-year individualized flexible treatment (IFT) phase. During the IFT phase, an assessment of disease stability will be performed at each monthly visit and subjects will receive either an active or a sham injection. Treatment with active will be interrupted when disease stability is reached. Maximum study duration per patient is 80 weeks.

Inclusion Criteria:

  • Age ≥ 18.
  • Signed informed consent must be obtained prior to participation in the study.
  • Patients with visual impairment due to ME secondary to CRVO diagnosed < 6 months prior to screening. Hemiretinal vein occlusions are classified as CRVO..
  • BCVA score between 78 and 23 letters, inclusive, using ETDRS visual acuity testing charts (approximate Snellen equivalent of 20/32 to 20/320) at both screening and baseline visits.

Exclusion Criteria:

  • Concomitant conditions or ocular disorders in the study eye at Screening or Baseline which could, in the opinion of the investigator, prevent response to study treatment or may confound interpretation of study results, compromise visual acuity or require medical or surgical intervention during the first 12-month study period (e.g. structural damage of the fovea, vitreous hemorrhage, retinal vascular occlusion other than CRVO, retinal detachment, macular hole, or choroidal neovascularization of any cause, diabetic retinopathy (except mild non-proliferative) and diabetic macular edema).  
  • Any active intraocular or periocular infection or active intraocular inflammation (e.g. infectious conjunctivitis, keratitis, scleritis, endophthalmitis, infectious blepharitis, uveitis) in study eye at Screening or Baseline.
  • Uncontrolled glaucoma in the study eye defined as intraocular pressure (IOP) > 25 mmHg on medication, or according to investigator's judgment, at Screening or Baseline.
  • Presence of amblyopia, amaurosis or ocular disorders in the fellow eye with BCVA < 20/200 at screening (except when due to conditions whose surgery may improve VA, e.g. cataract).
  • Previous treatment with any anti-VEGF therapy or investigational drugs in the study eye at any time prior to Baseline.
  • Previous use of intraocular or periocular steroids in study eye at any time prior to Baseline.
  • Macular laser photocoagulation (focal/grid) in the study eye at any time prior to Baseline and peripheral laser photocoagulation in the study eye within 3 months prior to the Baseline.
  • Intraocular surgery in the study eye during the 3 month period prior to Baseline.
  • Vitreoretinal surgery in the study eye at any time prior to Baseline.
  • Aphasia with the absence of posterior capsule in the study eye.

Other protocol-specified inclusion/exclusion criteria may apply.

Contact:

Middleburg Heights Office - Susan Rath 440-663-0022   •    srath@retina-assoc.com

For More Information:

https://clinicaltrials.gov/ct2/show/NCT03810313